Kisspeptin: The Upstream Hormone Signal You've Never Heard Of

Most people have heard of testosterone, oestrogen, and progesterone. Far fewer have heard of the peptide that tells the body to make all of them.

Kisspeptin was discovered in 1996 at the Penn State College of Medicine in Hershey, Pennsylvania. The naming convention in the research group was to prefix new discoveries with KISS — the team later admitted the name was partly a nod to Hershey's Kisses, the chocolate made in the same town. For the first five years after discovery, the scientific community classified kisspeptin as a tumour suppressor and largely ignored it.

Then in 2003, two independent research groups published back-to-back papers in the New England Journal of Medicine and PNAS showing the same unexpected finding: patients with loss-of-function mutations in the kisspeptin receptor (KISS1R, also called GPR54) failed to enter puberty. The peptide that had been dismissed as a cancer-biology curiosity turned out to be the master switch of the human reproductive axis.

Kisspeptin sits at the top of the hypothalamic–pituitary–gonadal (HPG) axis. It is produced by specialised neurons in the hypothalamus — most notably in the arcuate nucleus, where a subset of these neurons also co-express neurokinin B and dynorphin. This cluster is referred to as KNDy neurons (pronounced candy).

KNDy neurons generate the rhythmic pulses of GnRH (gonadotropin-releasing hormone) that the pituitary needs to release LH and FSH. LH and FSH in turn drive the gonads to produce testosterone, oestrogen, and progesterone. Without kisspeptin, the entire cascade silently stalls. No kisspeptin, no GnRH pulses, no LH surge, no ovulation, no testosterone synthesis.

This is what makes kisspeptin unusual among peptides of research interest. It does not act directly on muscle, skin, or gut tissue the way compounds like BPC-157 or GHK-Cu do. It acts as a signalling molecule one level upstream of every sex hormone in the body.

Kisspeptin has moved from obscure discovery to active clinical pipeline in two decades. Three developments are driving current interest.

First, Imperial College London is running phase-2 trials using kisspeptin-54 (a longer fragment of the native peptide) to restore hypothalamic function in women with hypothalamic amenorrhea — a condition common among endurance athletes and women with low body-fat levels where the HPG axis shuts down and menstruation ceases. Early results from the Waljit Dhillo group show kisspeptin administration can restore LH pulsatility and ovulation.

Second, KNDy neurons were identified in 2024 as the proximate cause of menopausal hot flashes. When oestrogen drops during menopause, KNDy neurons become hyperactive and trigger the thermoregulatory dysfunction that produces flushes. Fezolinetant (brand name Veozah), the first non-hormonal hot-flash drug, was approved by the FDA in 2023 and works by blocking a downstream target of this circuit (NK3R). It has since been approved in Australia by the TGA in 2024 — one of the first direct clinical applications of kisspeptin-pathway research.

Third, kisspeptin is being studied in early-stage trials for fertility treatment, sexual arousal disorders, and HPG-axis recovery after anabolic-androgenic steroid use. Results are preliminary but the direction of research is clearly toward human therapeutic applications.

The clinical research on kisspeptin skews heavily toward women's health, which is unusual in a field dominated by muscle and recovery compounds aimed at men.

Hypothalamic amenorrhea affects an estimated 1.6 million women in Australia and is frequently under-diagnosed. Current treatment is often limited to caloric rehabilitation and stress reduction, with combined oral contraceptives used to restore cycles cosmetically without fixing the underlying signalling defect. Kisspeptin offers a mechanistic intervention — restoring the upstream signal rather than masking it.

For menopausal symptoms, the KNDy-neuron research has already produced one approved drug (fezolinetant). More targeted interventions are in development. Kisspeptin itself has been tested for hot flashes in small clinical studies with mixed results, but the indirect pathway — via KNDy-neuron modulation — has produced the more successful clinical translation to date.

There is also early interest in kisspeptin for age-related decline in sex-hormone production in men and women, though this is further from clinical application.

Kisspeptin is not a TGA-approved therapeutic in Australia. Any clinical use currently takes place through authorised research trials, specialist compounding pharmacy pathways with a prescription, or academic research programmes.

Fezolinetant, the downstream KNDy-blocker, was registered on the Australian Register of Therapeutic Goods (ARTG) in 2024 for the treatment of moderate to severe vasomotor symptoms associated with menopause. It is prescription-only and not subsidised on the PBS as of mid-2026.

Kisspeptin itself as a research chemical is available from research-peptide vendors, but as with all Schedule 4 compounds it is not legal for therapeutic human use outside the regulated pathways above. Readers in Australia considering kisspeptin for any purpose should speak to a qualified clinician first, and should expect that most GPs and endocrinologists will be unfamiliar with the compound.

Kisspeptin is one of the more promising peptides in active clinical development, but several things are not yet established.

Long-term safety data in humans does not exist. All current trials have been short-duration. Whether repeated kisspeptin administration over years causes receptor desensitisation, downstream hormonal dysregulation, or other effects is unknown.

Optimal dosing for non-research uses is not established. The fragments studied in trials (kisspeptin-10, kisspeptin-54) have different half-lives and pharmacokinetics, and the optimal delivery route (intravenous infusion, subcutaneous, intranasal) varies by indication.

There is currently no rigorous evidence that kisspeptin is useful for recreational or lifestyle applications — enhancing libido in healthy individuals, improving athletic performance, or extending fertility in the absence of underlying hypothalamic dysfunction. The research showing benefits has consistently been conducted in populations with a defined clinical deficit.

For practical information on kisspeptin as a compound, see our full peptide profile at /peptides/kisspeptin, which covers the known research doses, fragment types, and supply context.

If you are new to peptides generally, the reconstitution guide at /guides/reconstitution-guide-beginners and the storage guide at /guides/how-to-store-peptides cover the basics that apply regardless of which peptide you are researching.

For Australian vendor information and compounding pharmacy pathways, our rated vendors page at /vendors provides an up-to-date comparison of sources that ship domestically.

This guide is for educational and informational purposes only. It is not medical advice. Kisspeptin is not an approved therapeutic in Australia and is classified as Schedule 4 (Prescription Only) when intended for therapeutic use. Any clinical application should be discussed with a qualified healthcare professional. The research information presented reflects the published scientific literature as of April 2026 and does not constitute a recommendation for use.